Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 39 years old.
- You have a newly diagnosed high-grade glioma (HGG) with an IDH1 mutation (but not an IDH2 mutation).
- You weigh at least 35 kg (77 lbs).
- You have not had extensive prior treatment for this tumor (only surgery, radiation, and/or temozolomide with radiation are allowed).
- You are able to swallow pills and have adequate organ function (kidneys, liver, bone marrow).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests a combination of two immunotherapy drugs, relatlimab and nivolumab, for people with certain brain tumors (high-grade glioma or DIPG) that have DNA repair issues. The treatment aims to help the immune system fight the tumor.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.